Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Concord Medical Services Holdings (CCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -94.57% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.92M USD | Price to earnings Ratio - | 1Y Target Price 1.2 |
Price to earnings Ratio - | 1Y Target Price 1.2 | ||
Volume (30-day avg) - | Beta -0.84 | 52 Weeks Range 3.80 - 10.90 | Updated Date 06/29/2025 |
52 Weeks Range 3.80 - 10.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -80.28% | Operating Margin (TTM) -202.5% |
Management Effectiveness
Return on Assets (TTM) -5.21% | Return on Equity (TTM) -38.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 523335017 | Price to Sales(TTM) 0.06 |
Enterprise Value 523335017 | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 9.77 | Enterprise Value to EBITDA -0.96 | Shares Outstanding 2815460 | Shares Floating 42075203 |
Shares Outstanding 2815460 | Shares Floating 42075203 | ||
Percent Insiders 18 | Percent Institutions 0.02 |
Upturn AI SWOT
Concord Medical Services Holdings
Company Overview
History and Background
Concord Medical Services Holdings Limited (CCM) was a China-based company providing cancer care services through a network of radiotherapy and diagnostic imaging centers. Founded in 2007, the company aimed to address the growing demand for advanced cancer treatment in China. It was delisted from the NYSE on August 17, 2022.
Core Business Areas
- Radiotherapy Centers: Managed and operated radiotherapy centers equipped with advanced technologies for cancer treatment.
- Diagnostic Imaging Centers: Operated diagnostic imaging centers offering services such as PET/CT scans and MRI.
- Equipment Sales: Sold medical equipment including radiotherapy and diagnostic imaging systems.
Leadership and Structure
Due to the delisting, current leadership and structure information is not publicly available. Historically, the company had a CEO and board of directors typical of a publicly traded company.
Top Products and Market Share
Key Offerings
- Radiotherapy Services: Provided advanced radiotherapy treatments for various types of cancer. Market share data is unavailable due to the company's delisting and the fragmented nature of the Chinese healthcare market. Competitors included large public hospitals and other private cancer treatment centers in China.
- Diagnostic Imaging Services: Offered PET/CT, MRI, and other advanced imaging services. Market share data is unavailable. Competitors included large public hospitals and other private diagnostic imaging centers in China.
- Medical Equipment: Sold radiotherapy equipment. Market share data is unavailable. Competitors included companies such as Varian Medical Systems (now Siemens Healthineers) and Elekta.
Market Dynamics
Industry Overview
Before its delisting, the market for cancer care services in China was growing rapidly, driven by an aging population and increasing cancer rates. There was a demand for advanced treatment options and diagnostic services.
Positioning
Concord Medical aimed to be a leading provider of radiotherapy and diagnostic imaging services in China, focusing on high-quality care and advanced technology. However, competition was stiff and reimbursement policies were complex.
Total Addressable Market (TAM)
Data on the total addressable market specific to Concord Medical's offerings is not readily available post-delisting. However, the oncology market in China represents a multi-billion dollar opportunity. Concord Medical was positioned to capture a portion of this TAM, particularly within the private healthcare sector.
Upturn SWOT Analysis
Strengths
- Established network of cancer treatment centers (historical)
- Access to advanced radiotherapy and diagnostic imaging technologies (historical)
- Experience in the Chinese healthcare market (historical)
Weaknesses
- Reliance on regulatory approvals in China
- Competition from large public hospitals
- Exposure to reimbursement risks
- Delisting from NYSE decreased investor confidence
Opportunities
- Expanding cancer care services to underserved regions in China
- Collaborating with international healthcare providers
- Developing new technologies for cancer treatment and diagnosis
Threats
- Changes in government regulations
- Increased competition from domestic and international players
- Economic slowdown in China
Competitors and Market Share
Key Competitors
- Varian Medical Systems (now Siemens Healthineers)
- Elekta AB (EKTAY)
- Various Chinese Public Hospitals
Competitive Landscape
Concord Medical faced competition from established international players like Varian and Elekta in equipment sales. In service provision, it competed with large public hospitals in China, which often had established relationships with patients and doctors. Concord Medical's advantages included its focus on advanced technology and service quality, while its disadvantages included smaller scale and greater regulatory hurdles.
Growth Trajectory and Initiatives
Historical Growth: Prior to delisting, Concord Medical had demonstrated some growth in revenue and the expansion of its service network. However, growth was subject to regulatory and competitive pressures.
Future Projections: Future growth projections are not applicable due to the company's delisting.
Recent Initiatives: There is no information available for any strategic initiatives after delisting.
Summary
Concord Medical Services Holdings (CCM) was a China-based cancer care company that was delisted from the NYSE. Prior to delisting, CCM aimed to be a leader in providing radiotherapy and diagnostic imaging services by leveraging advanced technology. However, the company faced regulatory hurdles and strong competition from established international players and public hospitals. Its future and operations following delisting are not public knowledge, impacting investor confidence. It is considered weak after the delisting.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical)
- Company Website (historical)
- Industry Reports (historical)
- News Articles (historical)
Disclaimers:
The information provided is based on historical data prior to Concord Medical Services Holdings's delisting. The current status of the company is unknown, and this analysis should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Concord Medical Services Holdings
Exchange NYSE | Headquaters - | ||
IPO Launch date 2009-12-11 | Chairman & CEO Dr. Jianyu Yang | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 595 | Website https://www.concordmedical.com |
Full time employees 595 | Website https://www.concordmedical.com | ||
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.